Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kala BioLTS:0JQ2 +10.35%24 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates LTS:0JQ2 with a GF Score™ of 24/100 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 952 Biotechnology companies, Kala Bio ranks worse than 105041.91% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kala Bio's Free Cash Flow for the
three
months ended in Mar. 2026 was $-2.90 Mil. Kala Bio's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Kala Bio's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Kala Bio's FCF Margin % or its related term are showing as below:
During the past 11 years, the highest FCF Margin % of Kala Bio was -1012.22%. The lowest was -2035.48%. And the median was -1502.29%.
LTS:0JQ2's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -81.28 * Ranked among companies with meaningful FCF Margin % only.
The historical data trend for Kala Bio's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0JQ2 vs GDTC, GTBP, INAB: FCF Margin % Comparison
For the Biotechnology subindustry, Kala Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kala Bio FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kala Bio's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Kala Bio's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kala Bio (LTS:0JQ2) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kala Bio and its competitors. According to the industry distribution chart, Kala Bio ranks #999999 out of 952 companies in the Biotechnology industry.
Is Kala Bio's FCF Margin % too high?
Kala Bio's current FCF Margin % is 0.00%. Based on the distribution chart, Kala Bio ranks #999999 out of 952 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kala Bio has a GF Score™ of 24/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kala Bio's FCF Margin % compare to GDTC and GTBP?
According to the Biotechnology industry distribution chart, Kala Bio ranks #999999 out of 952 companies for FCF Margin %. This places Kala Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kala Bio and its competitors. Kala Bio's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kala Bio stock overvalued right now?
Based on GuruFocus' analysis, Kala Bio (LTS:0JQ2) is currently considered Possible Value Trap. The current FCF Margin % is 0.00%. Kala Bio's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Kala Bio (LTS:0JQ2), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
24GF Score
Get the complete analysis for LTS:0JQ2
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JQ2 has been successfully added to your 
